文献速递临床试验与 GCP流行病学与生物统计

伤口内妥布霉素联合万古霉素预防胫骨骨折手术部位感染:TOBRA随机临床试验

Intrawound Tobramycin Plus Vancomycin to Prevent Surgical Site Infection in Tibial Fractures: The TOBRA Randomized Clinical Trial.
PubMed 文献 · JAMA · 2026-01-01

TOBRA随机临床试验在美国39个创伤中心纳入1660例高感染风险的成人胫骨平台或Pilon骨折患者,比较确定性固定时伤口内妥布霉素1.2g联合万古霉素1.0g与单用万古霉素1.0g对深部手术部位感染的影响。结果显示联合组182天深部感染概率7.4%,单药组6.6%,风险比1.11(95%贝叶斯可信区间0.75-1.66),未达到优效阈值,联合用药未减少深部感染。

要点

  • 高感染风险胫骨骨折固定时,伤口内妥布霉素联合万古霉素未比单用万古霉素降低深部手术部位感染。
  • 联合组182天深部感染概率7.4%,单药组6.6%,风险比1.11,未达优效阈值。
  • 所有次要结局均未达到优效阈值,不支持常规联合局部抗生素。

核心结论

  • 在手术治疗的成人关节周围胫骨骨折高感染风险患者中,确定性固定时伤口内加用妥布霉素粉末未比单用万古霉素粉末减少深部手术部位感染。

研究设计与样本

  • 开放标签、评估者设盲的随机临床试验,在美国39个创伤中心开展。
  • 纳入成人手术治疗的胫骨平台或Pilon骨折且符合3项感染风险升高标准之一者;2021年6月18日至2024年12月12日入组,最终随访至2025年7月15日。
  • 共随机1660例,1528例纳入主要分析(平均年龄47.0岁,标准差14.3;女性603例[39.5%],男性925例[60.5%])。

主要发现

  • 主要结局为确定性固定后182天内需手术处理的深部手术部位感染。
  • 妥布霉素联合万古霉素组753例中51例发生深部感染(182天概率7.4%),单用万古霉素组775例中47例(182天概率6.6%)。
  • 风险比1.11(95%贝叶斯可信区间0.75-1.66),优效后验概率29.7%。
  • 所有次要结局均未达到优效阈值。

关键数值与推荐

  • 干预:确定性固定时伤口内妥布霉素1.2g联合万古霉素1.0g粉末 vs 万古霉素1.0g粉末。
  • 主要结局:确定性固定后182天内需手术处理的深部手术部位感染。
  • 主要分析:联合组182天概率7.4%,单药组6.6%,风险比1.11(95%贝叶斯可信区间0.75-1.66)。

临床怎么用

  • 对高感染风险的关节周围胫骨骨折患者,确定性固定时不应常规在万古霉素粉末基础上加用妥布霉素粉末以预防深部手术部位感染。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Previous research has suggested that intrawound vancomycin powder reduces deep surgical site infections among patients with periarticular tibial fractures at high risk of infection. It is unknown whether the addition of tobramycin powder further decreases infection rates. OBJECTIVE: To compare whether the combination of tobramycin plus vancomycin vs vancomycin alone delivered as intrawound powder at the time of definitive fixation reduces deep surgical site infections. DESIGN, SETTING, AND PARTICIPANTS: Open-label, assessor-masked, randomized clinical trial conducted at 39 US trauma centers. Eligible patients were adults with an operatively treated periarticular tibial fracture (either tibial plateau or pilon) who met 1 of 3 criteria for elevated infection risk. Enrollment occurred between June 18, 2021, and December 12, 2024 (final follow-up, July 15, 2025). INTERVENTIONS: Intrawound tobramycin (1.2 g) plus vancomycin (1.0 g) powder vs intrawound vancomycin (1.0 g) powder delivered at the time of definitive fixation. MAIN OUTCOMES AND MEASURES: The primary outcome was a deep surgical site infection requiring surgical management within 182 days of definitive fracture fixation. Secondary outcomes included deep surgical site infections with pathogens that were gram-negative only, deep surgical site infections with at least 1 pathogen that was gram-positive, deep surgical site infections with polymicrobial cultures, deep surgical site infections with negative culture results, and cellulitis or skin infections treated only with antibiotics. RESULTS: Among the 1660 participants randomized, 1528 (mean age, 47.0 [SD, 14.3] years; 603 female [39.5%]; 925 male [60.5%]) were included in the primary analysis. Deep surgical site infections occurred in 51 of 753 participants (182-day probability, 7.4%) in the tobramycin plus vancomycin group and 47 of 775 participants (182-day probability, 6.6%) in the vancomycin alone group (hazard ratio, 1.11; 95% bayesian credible interval, 0.75-1.66; posterior probability of superiority, 29.7%). The threshold required for superiority was not reached for any secondary outcome. CONCLUSIONS AND RELEVANCE: Among patients with operatively treated periarticular tibial fractures at high risk of infection, adding intrawound tobramycin powder to vancomycin powder at the time of definitive fixation did not reduce deep surgical site infections compared with vancomycin powder alone. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02227446.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. O'Toole RV, O'Hara NN, Carlini AR, et al. Intrawound Tobramycin Plus Vancomycin to Prevent Surgical Site Infection in Tibial Fractures: The TOBRA Randomized Clinical Trial. JAMA. 2026. PMID: 41984450. doi:10.1001/jama.2026.4023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。